Effect of continued cannabis use on medication adherence in the first two years following onset of psychosis by Schoeler, T et al.
1. Introduction
Despite the effectiveness of antipsychotic medication in preventing relapse following the first 
episode of psychosis (FEP) (Leucht et al., 2012), relapse is a common occurrence, often due 
to non-adherence to prescribed medication (Verdoux et al., 2000; Coldham et al., 2002; Üçok 
et al., 2006; Morken et al., 2008; Gearing et al., 2009; Hill et al., 2010; Lambert et al., 2010; 
Caseiro et al., 2012; Levy et al., 2012; Barbeito et al., 2013; Hui et al., 2013). Although the 
reported rates vary considerably across studies (Sendt et al., 2015), estimates from systematic 
reviews indicate that an average of 26% of patients with psychosis do not adhere to their 
treatment plan (Nose et al., 2003). Particularly during the early stages of psychosis the rates 
of medication non-adherence are high (>50%) (Coldham et al., 2002; Schimmelmann et al., 
2007; Lambert et al., 2010; Schoeler et al., 2016), which is consistent with the finding that 
young patients are more likely than older ones to be non-adherent (Coldham et al., 2002; 
Kampman et al., 2002). For instance, more than 60% of FEP patients had at least one or more 
gaps in their antipsychotic medication use in the first year following their first episode of 
psychosis (Mojtabai et al., 2002). This early stage is also considered the “critical period” that 
determines long-term outcome in psychosis (Birchwood et al., 1997) and during which 
antipsychotic medications, if taken regularly, appear to be more effective in improving 
outcome than in the later stages of the illness (Hogarty 1993). Therefore, better understanding 
of factors that adversely influence adherence to medication treatment in the early period 
following onset of psychosis is particularly important in order to develop interventions that 
may help improve medication and long-term outcome in psychosis.
However, there is uncertainty regarding the factors that characterise non-adherent patients 
with psychosis. Although experience of side effects and lack of insight seem intuitively to be 
the most important contributors to non-adherence, evidence does not always support this 
(Mueser et al., 1990; Coldham et al., 2002; Mutsatsa et al., 2003; Kamali et al., 2006; De 
Haan et al., 2007). Anecdotal evidence from clinical settings suggests that another potentially 
important factor affecting adherence to antipsychotic medications is drug use, particularly use 
of cannabis use. However, comorbid cannabis use has often not been considered in 
multifactorial prediction models (Mueser et al., 1990; Kampman et al., 2002; Drake et al., 
2015), despite being the most commonly used drug of abuse prior to (Van Mastrigt et al., 
2004) and following the onset (Lange et al., 2014) of psychosis. While some evidence 
regarding the association between cannabis use and medication adherence exist(Foglia et al., 
under review), current evidence remains inconclusive due to limitations of existing studies 
such as underpowered samples (Verdoux et al., 2000; Miller et al., 2009; Schimmelmann et 
al., 2012), inclusion of patients that are at different stages of their illness (Rittmannsberger et 
al., 2004; Pogge et al., 2005; Novick et al., 2010; Jonsdottir et al., 2013) or cross-sectional 
study designs (Jonsdottir et al., 2013). In particular, lack of consideration of different patterns 
of cannabis use following onset of psychosis (Kampman et al., 2002; Perkins et al., 2006) 
limits the interpretability of current evidence, especially because cannabis is a 
pharmacologically complex plant whose effects are likely to depend on the type and dose of 
cannabis used, as well as pattern of its use (Di Forti et al., 2015; Schoeler et al., 2016; 
Schoeler et al., 2016). Furthermore, studies have often grouped cannabis users with users of 
other substances (Verdoux et al., 2000; Mutsatsa et al., 2003; Opolka et al., 2003; Kamali et 
al., 2006) which prevents conclusions being drawn about whether the effects may be 
attributed to a specific drug. For instance, users of illicit drugs may not take their 
antipsychotic medication so as not to blunt the pleasurable effects of the substance. Hence, it 
is important to examine whether medication non-adherence is generally associated with the 
use of any illicit drugs or is specifically associated with cannabis use. There is thus a need to 
distinguish between the different substances of use including cannabis, alcohol, cigarettes and 
other illicit drugs. Finally, it may be argued that worsening of psychotic symptoms (Schoeler 
et al., 2016) and cognitive function (Schoeler and Bhattacharyya 2013) as a result of cannabis 
use may interfere with the ability to regularly take the prescribed dose of medication. If this 
was the case, no link should exist between cannabis use and medication adherence in those 
whose illness course is not affected by the use of cannabis, which has not been examined 
previously.
In order to address limitations of existing evidence and to extend current evidence, this study 
has the following aims:
(1) To systematically evaluate the effect of different patterns of cannabis use following 
the onset of psychosis on the risk of non-adherence to prescribed antipsychotic 
medication
(2) To evaluate and control for the effects of patterns of use of other commonly used non-
prescription psychoactive substances following onset of psychosis, including alcohol, 
cigarette and illicit drugs other than cannabis
(3) To control for important confounders including clinical and demographic 
characteristics
(4) To test whether an association between cannabis use and non-adherence is present in 
a subgroup of patients whose illness course is not affected by cannabis use (i.e. 
including only non-relapsing FEP patients)
2. Method
As part of a follow-up study aiming to investigate the role of cannabis within the first two 
years following onset, we recruited patients with first-episode non-organic [non-affective 
(ICD10 codes F20-F29) or affective (F30-F33)] psychosis (WHO 2004), aged 18-65 who 
were referred to local psychiatric services in South London. We have previously reported on 
methods for evaluation of subjects and data acquisition (Schoeler et al., 2016; Schoeler et al., 
2016). This study was granted ethical approval by South London & Maudsley NHS 
foundation trust and Institute of Psychiatry Local Research Ethics Committee. All subjects 
included in the study gave written informed consent. 
2.1 Measures
Cannabis use was assessed using a modified version of the Cannabis Experience 
Questionnaire (Schoeler et al., 2016), collecting data on premorbid cannabis use, as well as 
use over the first two years following onset of psychosis. Cannabis users were classified 
based on their pattern of use following onset, depending on continuity and type (hash-like vs. 
skunk-like) (Di Forti et al., 2014; Schoeler et al., 2016) of cannabis use. Several covariates 
were included, based on previous literature (Verdoux et al., 2000; Coldham et al., 2002; 
Kampman et al., 2002; Mutsatsa et al., 2003; Kamali et al., 2006; Perkins et al., 2006; De 
Haan et al., 2007; Miller et al., 2009; Barbeito et al., 2013; Colizzi et al., 2015), including 
alcohol use, cigarette use, illicit drug use, gender, ethnicity, age of onset of illness, severity of 
illness at onset (measured as care intensity at onset, cf. below) and diagnosis.
2.2 Data analysis
Data analysis was performed using R (R Core Team 2015).  The cannabis profile variable 
was coded as an ordered categorical variable (cf. Table 2.), with the never (regular) user 
group acting as the reference group. As the main outcome of interest, medication adherence 
within the first two years following onset was assessed using the Life Chart Schedule (WHO 
1992; Susser et al., 2000).  Similar to previous reports (Faridi et al., 2012), the variable was 
dichotomized (adherence vs. non-adherence), rating a patient as compliant if the prescribed 
medication was taken regularly for more than 66%  of the time within the two years 
following the onset of illness (i.e. non-adherent for less than 34% of the time). Several 
covariates were included, including: 
a) Alcohol use: the alcohol use variable was dichotomized, classifying subjects as 
alcohol users if they had a history of daily use for at least one month within the first 
two years following onset of illness
b) Other drug use: other drug use was defined as use of illicit drugs other than cannabis 
within the first two years following onset. This variable was coded as a categorical 
variable [2=regular use (6 times or more); 1=experimental use (less than 6 times); 0 
(reference group)=no use]
c) Cigarette use: the variable assessing cigarette use in the first two years following 
onset was coded as a categorical variable [2=continued use (>12 months of regular 
use); 1=intermittent use (>2 months of regular use); 0 (reference group) = no regular 
use];
d) Diagnosis [affective vs. non-affective psychosis] was assessed based on ICD-10 
diagnosis using OPCRIT(McGuffin et al., 1991) criteria]
e) Ethnicity was recorded according to the classification proposed by the UK Office for 
National Statistics(ONS 2012) [ 0 (reference group)=White; 1=Asian; 2=African; 
3=Mixed/multiple ethnic groups]
f) Age of onset of illness was included as a categorical variable [0 (reference 
group)=younger than 21 years old; 1=between 21 and 45 years old; 2=older than 45 
years old], based on the age on the date of referral for a first episode psychosis
g) Care intensity was coded as a categorical variable, rating each subject’s intensity of 
service use when presenting to the psychiatric services for a first episode psychosis 
[0=Required only community treatment without crisis intervention; 1=Required crisis 
intervention without hospital admission; 2= Required hospital admission]
First, we ran simple logistic regression models to examine the uncontrolled effect of each of 
the specified predictors of interest separately. Then we employed multiple regression models 
to test whether the categorical cannabis variable remained a significant predictor after 
controlling for the effects of those specified covariates. It may be argued that some patients 
may struggle to take antipsychotic medication as a result of being too unwell and having a 
relapsing course of illness, rather than necessarily being an effect of cannabis use. Although 
this is not easy to disentangle, we attempted to address this issue by investigating whether the 
association between cannabis use and risk of non-adherence was also present in those patients 
who did not have a relapsing course of illness. Relapse was defined as admission to a 
psychiatric inpatient unit owing to exacerbation of psychotic symptoms within two years 
following first presentation to psychiatric services and receiving a diagnosis of psychosis 
(Addington et al., 2012; Olivares et al., 2013; Schoeler et al., 2016).
3. Results3.1 Sample characteristics
Over the first two years following onset, 59.2% (n=138) of the patients were not adherent to 
their prescribed medication (cf. Table 1.). Compared to those who were adherent, the non-
adherent group differed significantly in several variables, i.e. they were different in their 
cannabis use following onset (χ²=17.52; p=0.002), more likely to be male (χ²=5.36; p=0.02), 
and of different ethnic background (χ²=9.66; p=0.02). The two groups (adherent vs. non-
adherent) did not significantly differ with regard to other substance use including cigarettes 
(χ²=2.36; p=0.31), alcohol (χ²=0.14; p=0.71) and illicit drugs (χ²=1.03; p=0.60). In the group 
classified as regular users of other illicit drugs following the onset (n=26, 11.2%), n=18 
(69.2%) used cocaine, n=8 (30.8%) used opioids, n=8 (30.8%) used amphetamines, n=3 
(11.5%), used hallucinogens, n=2 (7.7%) used poppers and n=1 (3.8%) used ketamine. 40.3% 
(n=94) have never used cannabis regularly in their life. A subset of patients (19.3%, n=45) 
used cannabis regularly prior to but did not report use following onset of psychosis. Cannabis 
use following onset was reported by n=94 (40.3%) patients (mean age of onset of use 17.3 
years, 3.99 SD), including n=34 (14.6%) who used it intermittently and n=60 (25.8%) who 
used continuously (each month within the two years following onset). Most of the post-onset 
users had a history of regular cannabis use prior to onset (n=91, 96.8%) and used cannabis 
during the month preceding onset of illness [n=80, 93% (missing data for n=13)]
=========================== TABLE 1. ===============================
3.2 Cannabis use and risk of non-adherence
As shown in the simple logistic regression model in Table 2., out of the five different 
cannabis use groups, only those classified as continued users of skunk-like cannabis were 
significantly more likely to be non-adherent with their prescribed medication when compared 
to never regular users [ORsimple=4.58; 95% CI 2.08-10.99, p<0.001]. The other cannabis use 
groups were not significantly different when compared to the never regular user group, 
including former (regular) cannabis users [ORsimple=0.84; 95% CI 0.41-1.71, p=0.63], 
intermittent cannabis users [ORsimple=1.55; 95% CI 0.70-3.52, p=0.29] or continued users of 
hash-type cannabis [ORsimple=1.60; 95% CI 0.37-8.15, p=0.54]. The magnitude of effect of 
continued use of skunk-like cannabis remained significant in the multiple logistic regression 
analysis [ORmultiple=5.26; 95% CI 1.91-15.68, p=0.002], in which the effect of all covariates 
specified in Table 2. was controlled for. In this controlled model, the effect of gender was no 
longer significant [ORmultiple =1.7; 95% CI 0.91-3.21, p=0.10], while African [ORmultiple 
=2.41; 95% CI 1.21-4.88, p=0.01] and Asian [ORmultiple =4.53; 95% CI 1.22-19.78, p=0.03] 
ethnicity remained significant predictors for non-adherence. When the analysis was restricted 
to patients with a non-relapsing illness course (cf. Table 3.), cannabis remained a significant 
predictor for medication non-adherence in simple [ORsimple=4.11; 95% CI 1.42-13.84, 
p=0.01] and multiple logistic regression analyses [ORmultiple=4.61; 95% CI 1.13-22.23, 
p=0.04] 
=========================== TABLE 2. ===============================
=========================== TABLE 3. ===============================
4. Discussion
More than half of our patients with a first episode psychosis did not comply with their 
antipsychotic medication within the first two years following onset, which is consistent with 
the high prevalence rates in FEP samples reported previously (Coldham et al., 2002; 
Schimmelmann et al., 2007; Lambert et al., 2010; Schoeler et al., 2016). Our results showed 
that ongoing cannabis use following onset of psychosis was significantly associated with 
medication non-adherence even after controlling for potential confounders such as other 
illicit drug use and clinical and demographic characteristics. More specifically, when 
compared to never regular users, risk of non-adherence was greater in those who used skunk-
like forms of cannabis continuously i.e. used at least monthly throughout the first 2 years 
following onset of psychosis. Risk was not significantly greater in those who used it more 
sporadically following onset or used milder forms of cannabis (hash-like), suggesting that 
potency and usage pattern of cannabis may determine the magnitude of effect of cannabis use 
on non-adherence. It is likely that the greater effect of skunk-like cannabis on medication 
adherence merely reflects the effect of exposure to the higher dose of delta-9-
tetrahydrocannabinol present in skunk compared to hash-type cannabis and is consistent with 
previous evidence (Di Forti et al., 2014; Schoeler et al., 2016). This is in line with existing 
evidence, in which reductions in cannabis use were linked to improvements in adherence in 
FEP patients over the long-term (Barbeito et al., 2013). Our finding may also explain the 
absence of effect of cannabis use on medication adherence reported by studies that assessed 
cannabis use only at onset of psychosis (Coldham et al., 2002; De Haan et al., 2007). Hence, 
focusing on use patterns following onset may be a more useful indicator of adherence for 
clinicians during the early stages of the illness. 
These results also suggest that this effect on non-adherence is a specific effect of cannabis 
use as no significant effect of other substances such as cigarette, alcohol or illicit drugs other 
than cannabis was observed on non-adherence. This is similar to results from other studies, in 
which use of illicit drugs (excluding cannabis) (Barbeito et al., 2013), alcohol (Verdoux et al., 
2000; Coldham et al., 2002; Mutsatsa et al., 2003; Colizzi et al., 2015) or cigarette (Barbeito 
et al., 2013) was not predictive of adherence to  medication. Only a few predictors other than 
cannabis use were significantly linked to medication non-adherence. For instance, a greater 
risk of non-adherence was found in patients who were of African or Asian ethnicity, 
consistent with previous reports (Opolka et al., 2003). Male gender was significantly linked 
to medication non-adherence in univariate analysis but was no longer predictive in the 
controlled models, consistent with previous evidence reporting no gender effect (Mutsatsa et 
al., 2003; Kamali et al., 2006; Miller et al., 2009; Barbeito et al., 2013). Age of onset of 
psychosis, illness severity at onset (indexed care intensity at onset) and diagnosis were not 
associated with  mediation non-adherence ,which is generally consistent with previous studies 
(Verdoux et al., 2000; Mutsatsa et al., 2003; De Haan et al., 2007; Barbeito et al., 2013), 
although inconsistencies exist (Kampman et al., 2002; García et al., 2016).
Recent evidence from a large study in first episode psychosis suggests that failure of 
treatment with prescribed antipsychotic medications may mediate the association between 
cannabis use and poor outcome characterized by relapse of psychosis leading to 
hospitalization (Patel R et al., 2016). The authors however could not establish whether 
treatment failure was a result of treatment resistance or non-adherence to antipsychotic 
medications. The present study extends these results suggesting that cannabis use may cause 
failure of treatment with antipsychotic medications by increasing the risk of non-adherence to 
treatment. Whether it also increases the risk of resistance to antipsychotic medications is yet 
to be tested. There are several potential mechanisms through which cannabis use may be 
increase the risk of medication non-adherence, though these are yet to be tested. For instance, 
cannabis use, particularly the use of high-potency forms of cannabis such as skunk, may 
increase the risk of non-adherence through its dose-dependent effects on memory as reported 
by experimental (Curran et al., 2002) and observational studies (Bolla et al., 2002; Schoeler 
and Bhattacharyya 2013; González-Pinto et al., 2016), resulting in cannabis-using patients 
forgetting to take prescribed medications. Prospective memory (i.e. the ability to remember to 
do things in the future such as taking medication) may be the memory domain most affected 
by cannabis in those using the substance (Schoeler et al., 2016). Increased risk of non-
adherence may also reflect the adverse effects of cannabis use on illness course via its effects 
on symptoms (González-Ortega et al., 2015; Schoeler et al., 2016) and risk of relapse 
(Schoeler et al., 2016) - adverse affects that have particularly been linked to the use of skunk-
type forms of cannabis (Di Forti et al., 2015; Sideli et al., 2015; Schoeler et al., 2016). 
Experimental studies using delta-9-tetrahydorcannabinol, the main psychoactive ingredient in 
cannabis suggest that it can induce acute psychotic symptoms and alter memory processing in 
healthy volunteers (Bhattacharyya et al., 2009; Bhattacharyya et al., 2012; Bhattacharyya et 
al., 2012; Bhattacharyya et al., 2015) and affect them to a greater extent in patients with 
psychosis (D’Souza et al., 2005). Nevertheless, when restricting the analysis to a subsample 
of patients in whom illness course was not as adversely affected by cannabis use as evident 
from the fact that they did not experience relapses over the duration of follow-up, cannabis 
use remained a significant predictor for non-adherence. This may suggest that it is unlikely 
that non-adherence to antipsychotic medications is merely a result of a poor illness course 
rather than being a direct effect of cannabis use on adherence. 
Some limitations have to be pointed out when interpreting these results. First, we assessed 
adherence to medication based on self-reports without taking into account drug-level 
measurements or pill counts. Nevertheless, self-reports are considered as a valid and  
appropriate method of measuring adherence especially when validated with serum 
concentration of medication (Jónsdóttir et al., 2010). While self-reports are likely to 
overestimate adherence, this is unlikely to have been systematically different in any of the 
cannabis use groups compared to others. Similarly, cannabis use was assessed based on self-
reports, but these measures provide generally reliable estimates as observed when compared 
with biological measures (Di Forti et al., 2012), which has been done in this study. Further 
investigations on this topic should therefore add biological measures of cannabis use and 
medication adherence obtained from commonly employed tests such as hair analyses or blood 
tests. Although it may be argued that we did not control for the type of medication that was 
prescribed following onset, this has previously not been linked to risk of medication non-
adherence (Miller et al., 2009). Finally, we did not further evaluate mechanisms of action, 
e.g. whether level of insight into illness or response to antipsychotic medication played a role 
in the association between cannabis use and risk of non-adherence. Future studies should 
therefore explore the different pathways that may help explain the relationship we found in 
this study.  It is worth noting that these results do not allow us to disentangle the possibilities that the 
effect of cannabis use on medication adherence as observed here may have been a result of its effect 
on symptoms and clinical presentation or an independent effect on compliance with antipsychotic 
medications or indeed both. Future studies may attempt to disentangle these possibilities. In this 
context it should also be pointed out that we did not further investigate whether the effects of 
cannabis use on outcome were mediated by its effect on medication adherence, which may be 
investigated in future using appropriately powered samples. Finally, it should be noted that 
we included a selective subset of inner city FEP patients. Hence, future studies need to 
replicate these results in patients from different geographical areas as well in patients at a 
later stage of their illness to confirm whether the results reported here also apply to other 
clinical settings and to those with a more chronic course of illness.
To summarise, continued use of high-potency cannabis is associated with a significantly 
greater risk of poor-adherence to antipsychotic medications in FEP patients. As cannabis use 
is a potentially preventable risk factor, interventions aimed at improving medication 
adherence in FEP should specifically target cannabis use, as reduction in cannabis use may 
lead to a more favourable illness course (Barbeito et al., 2013) and reduced cost of care 
(Offord et al., 2013) in FEP.  
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Table 1. Sample characteristics
N 233
Female 92 (39.5%)Gender 
N (%) Male 141 (60.5%)
Ethnicity White 79 (33.9%)
Asian 15 (6.4%)
African 126 (54.1%)
Mixed/Other 13 (5.6%)
Onset characteristics 
Mean age at onset (SD) 28.38 (8.47)
Affective 42 (18%)Diagnosis
N (%) Non-affective 191 (82%)
Community treatment 36 (15.5%)
Crisis intervention 17 (7.3%)
Onset care intensity
Hospitalisation 180 (77.3%)
No 97 (41.6%)History of (regular) 
cannabis use Yes 136 (58.4%)
2-year follow up characteristics 
FEP only 143 (61.4%)Course type
Episodic 90 (38.6%)
Compliant 95 (40.8%)Medication 
adherence Non-compliant 138 (59.2%)
No use 99 (42.5%)
Intermittent use 18 (7.7%)
Cigarette use
Continued use 116 (49.8%)
No use 201 (86.3%)Alcohol use
Continued use 32 (13.7%)
Never 94 (40.3%)
Former 45 (19.3%)
Intermittent 34 (14.6%)
Continued (Hash-type) 8 (3.4%)
Cannabis use
Continued (Skunk-type) 52 (22.3%)
No use 193 (82.8%)
Experimental 14 (6%)
Other illicit drug use
Regular use 26 (11.2%)
Table 2. Predictors for risk of m
edication non-adherence: Logistic regression m
odels (N
=233)
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Table 3. Sensitivity analysis: Cannabis use and risk of medication non-adherence in non-
relapsing FEP patientsa
Simple Multipleb
OR 95% CI p OR 95% CI p
Cannabis use
   Never 1 1
   Former 0.64 0.26 - 1.52 0.32 0.6 0.19 - 1.82 0.37
   Intermittent 1.71 0.64 - 4.75 0.29 2.62 0.73 - 10.19 0.15
   Continued (Hash-type) 0.43 0.02 - 3.55 0.47 0.35 0.01 - 3.93 0.43
   Continued (Skunk-type) 4.11 1.42 - 13.84 0.01 4.61 1.13 - 22.23 0.04
a Includes only patients with good clinical outcome (non-relapsing within the first two years following onset, n=143)
b Multiple logistic regression analysis including all covariates listed in this Table 2.
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Cannabis use 0.002
   Never 46 (48.9%) 48 (51.1%) 1 1
   Former 24 (53.3%) 21 (46.7%) 0.84 0.41 - 1.71 0.63 1.13 0.47 - 2.73 0.79
   Intermittent 13 (38.2%) 21 (61.8%) 1.55 0.70 - 3.52 0.29 2.03 0.76 - 5.68 0.16
   Continued (Hash-type) 3 (37.5%) 5 (62.5%) 1.60 0.37 - 8.15 0.54 1.50 0.28 - 9.22 0.64
   Continued (Skunk-type) 9 (17.3%) 43 (82.7%) 4.58 2.08 - 10.99 <0.001 5.26 1.91 - 15.68 0.002
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Cigarette use 0.31
   No use 46 (46.5%) 53 (53.5%) 1 1
   Intermittent use 7 (38.9%) 11 (61.1%) 1.36 0.50 - 3.98 0.55 0.88 0.26 - 3.06 0.84
   Continued use 42 (36.2%) 74 (63.8%) 1.53 0.89 - 2.65 0.13 0.88 0.41 - 1.89 0.74
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Onset care intensity 0.21
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  Non-affective 73 (38.2%) 118 (61.8%) 1.78 0.91 - 3.51 0.09 2.07 0.96 - 4.54 0.07
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   Never 1 1
   Former 0.64 0.26 - 1.52 0.32 0.6 0.19 - 1.82 0.37
   Intermittent 1.71 0.64 - 4.75 0.29 2.62 0.73 - 10.19 0.15
   Continued (Hash-type) 0.43 0.02 - 3.55 0.47 0.35 0.01 - 3.93 0.43
   Continued (Skunk-type) 4.11 1.42 - 13.84 0.01 4.61 1.13 - 22.23 0.04
a Includes only patients with good clinical outcome (non-relapsing within the first two years following onset, n=143)
b Multiple logistic regression analysis including all covariates listed in this Table 2.
Abstract
Uncertainty exists whether the use of non-prescription psychoactive substances following 
onset of a first episode of psychosis (FEP), in particular cannabis use, affects medication 
adherence. Data from FEP patients (N=233) obtained through prospective assessments 
measured medication adherence and pattern of cannabis and other substance use in the first 
two years following onset of psychosis. Multiple logistic regression analyses were employed 
to compare the different substance use groups with regard to risk of medication non-
adherence, while controlling for confounders. The proportion of non-adherent patients was 
higher in those who continued using high-potency forms of cannabis (skunk-like) following 
the onset (83%) when compared to never regular users (51%), corresponding to an Odds 
Ratio (OR) of 5.26[95% Confidence Interval (CI) 1.91-15.68]. No significant increases in 
risk were present in those who used cannabis more sporadically or used milder forms of 
cannabis (hash-like). Other substances did not make an independent contribution in this 
model, including cigarette use ([OR 0.88, 95% CI 0.41-1.89]), alcohol use ([OR 0.66, 95% CI 
0.27-1.64]) or regular use of other illicit drugs ([OR 1.03, 95% CI 0.34-3.15]) following the 
onset. These results suggest that continued use of high-potency cannabis following the onset 
of psychosis may adversely affect medication adherence.
Keywords: Cannabis, THC, first episode psychosis, epidemiology
Highlights
• The study examined the effect of cannabis use on risk of medication non-adherence in 
psychosis
• Use of high-potency forms of cannabis following the onset predicted medication non-
adherence
• The effect remained significant when potential confounders were considered
• More sporadic use of cannabis was not linked to medication non-adherence
• Similarly, the use of milder forms of cannabis (hash-like) was not associated with 
non-adherence
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